ATE347908T1 - Vorbeugung von gewebeadhäsion - Google Patents

Vorbeugung von gewebeadhäsion

Info

Publication number
ATE347908T1
ATE347908T1 AT03702560T AT03702560T ATE347908T1 AT E347908 T1 ATE347908 T1 AT E347908T1 AT 03702560 T AT03702560 T AT 03702560T AT 03702560 T AT03702560 T AT 03702560T AT E347908 T1 ATE347908 T1 AT E347908T1
Authority
AT
Austria
Prior art keywords
post
operative
adhesions
prevention
formation
Prior art date
Application number
AT03702560T
Other languages
English (en)
Inventor
Philippe Koninckx
Peter Carmeliet
Desire Collen
Sanabria Carlos Roger Molinas
Original Assignee
Vlaams Interuniv Inst Biotech
Thromb X
Leuven K U Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201983A external-priority patent/GB2384428A/en
Priority claimed from GB0202379A external-priority patent/GB2384706A/en
Priority claimed from GB0225128A external-priority patent/GB0225128D0/en
Application filed by Vlaams Interuniv Inst Biotech, Thromb X, Leuven K U Res & Dev filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE347908T1 publication Critical patent/ATE347908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AT03702560T 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion ATE347908T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201983A GB2384428A (en) 2002-01-29 2002-01-29 Inhibitors of HIF
GB0202379A GB2384706A (en) 2002-02-04 2002-02-04 Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
GB0225128A GB0225128D0 (en) 2002-10-29 2002-10-29 Laparoscopy and adhesion formation

Publications (1)

Publication Number Publication Date
ATE347908T1 true ATE347908T1 (de) 2007-01-15

Family

ID=27669901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702560T ATE347908T1 (de) 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion

Country Status (5)

Country Link
US (1) US20050163781A1 (de)
EP (1) EP1482975B1 (de)
AT (1) ATE347908T1 (de)
DE (1) DE60310383T2 (de)
WO (1) WO2003063904A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2005007828A2 (en) * 2003-07-14 2005-01-27 Prolx Pharmaceuticals, Inc. Regulation of hif protein levels via deubiquitination pathways
US7807814B2 (en) 2003-12-23 2010-10-05 The Trustees Of The University Of Pennsylvania Compositions and methods for combined therapy of disease
WO2006026485A2 (en) * 2004-08-25 2006-03-09 Isis Pharmaceuticals, Inc. Modulation of hif1-beta expression
PL1869085T3 (pl) 2005-03-24 2012-09-28 Thrombogenics Nv Nowe przeciwciało anty-PIGF
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
ES2462416T3 (es) * 2007-08-06 2014-05-22 Senju Pharmaceutical Co., Ltd. Producto farmacéutico que contiene un inhibidor de la expresión de HIF-1 alfa y HIF-2 alfa
DK2785739T3 (en) 2011-12-01 2017-07-03 Thrombogenics Nv IMPROVING THE RESULT OF TREASURE CULECTOMY
DK3082860T3 (da) * 2013-12-18 2021-01-25 Csl Ltd Fremgangsmåde til behandling af sår
AU2017231765A1 (en) 2016-03-10 2018-08-23 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
PT3448421T (pt) * 2016-04-29 2022-01-14 Univ Leland Stanford Junior Métodos e composições para a prevenção e tratamento de aderências cirúrgicas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation

Also Published As

Publication number Publication date
EP1482975A2 (de) 2004-12-08
US20050163781A1 (en) 2005-07-28
WO2003063904A2 (en) 2003-08-07
EP1482975B1 (de) 2006-12-13
WO2003063904A3 (en) 2004-01-15
DE60310383T2 (de) 2007-09-20
DE60310383D1 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
DE60310383D1 (de) Vorbeugung von gewebeadhäsion
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE408601T1 (de) Fredericamycin-derivate
NO20055305D0 (no) Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE464889T1 (de) Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
DE69839877D1 (de) Behandlung und vorbeugung von adhesionen
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
BR0313555A (pt) Aplicação de inibidores de ikb-cinase na terapia da dor
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
MX2009004049A (es) Nuevos derivados de fluoreno, composiciones que los contienen y sus usos como inhibidores de la proteina chaperona hsp90.
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties